Athenex, Inc. (ATNX) financial statements (2020 and earlier)

Company profile

Business Address 1001 MAIN STREET
BUFFALO, NY 14203
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments10410751
Cash and cash equivalents615039
Short-term investments425812
Restricted cash and investments25  
Receivables17138
Inventory, net of allowances, customer advances and progress billings282917
Inventory282917
Deferred costs  0
Other undisclosed current assets39227
Total current assets:21417184
Noncurrent Assets
Operating lease, right-of-use asset9
Property, plant and equipment191110
Long-term investments and receivables  0
Long-term investments  0
Intangible assets, net (including goodwill)464846
Goodwill373738
Intangible assets, net (excluding goodwill)9119
Other noncurrent assets  0
Deferred tax assets, net00
Total noncurrent assets:746057
TOTAL ASSETS:288231140
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities865144
Accounts payable161317
Accrued liabilities703827
Debt111
Due to related parties  0
Other undisclosed current liabilities3  
Total current liabilities:905245
Noncurrent Liabilities
Long-term debt and lease obligation9460
Long-term debt, excluding current maturities145 
Finance lease, liability0
Capital lease obligations00
Operating lease, liability8
Liabilities, other than long-term debt354
Deferred revenue and credits2
Deferred compensation liability, classified332
Deferred rent credit 2
Other undisclosed noncurrent liabilities52  
Total noncurrent liabilities:63515
Total liabilities:15310250
Stockholders' equity
Stockholders' equity attributable to parent14713990
Common stock000
Treasury stock, value(7)(7)(7)
Additional paid in capital700591424
Accumulated other comprehensive loss(0)(1)(0)
Accumulated deficit(546)(444)(326)
Stockholders' equity attributable to noncontrolling interest(12)(11)1
Total stockholders' equity:13512991
TOTAL LIABILITIES AND EQUITY:288231140

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Revenues888938
Revenue, net38
Cost of revenue
(Cost of Goods and Services Sold)
(68)(47)(25)
Gross profit:204213
Operating expenses(144)(169)(123)
Operating loss:(124)(127)(110)
Nonoperating income
(Investment Income, Nonoperating)
1  
Interest and debt expense(2) (6)
Loss from continuing operations before equity method investments, income taxes:(125)(127)(116)
Other undisclosed loss from continuing operations before income taxes(4)(2)(15)
Loss from continuing operations before income taxes:(129)(129)(131)
Income tax expense(1)(0)(0)
Net loss:(130)(129)(131)
Net income attributable to noncontrolling interest1110
Net loss available to common stockholders, diluted:(129)(117)(131)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Net loss:(130)(129)(131)
Other comprehensive income (loss)0(1)1
Comprehensive loss:(130)(129)(130)
Comprehensive income, net of tax, attributable to noncontrolling interest1110
Comprehensive loss, net of tax, attributable to parent:(129)(118)(130)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: